Jubilant Life Sciences’ material wholly owned subsidiary Jubilant Pharma, through one of its wholly owned subsidiaries, has received Abbreviated New Drug Application (ANDA) final approval for Amlodipine and Olmesartan Medoxomil Tablets 5mg/20mg, 5mg/40mg, 10mg/20mg and 10mg/40mg, the generic version of Azor of Daiichi Sankyo, which is used for the treatment of hypertension.
This is the third approval that the company has received from the USFDA during the current financial year. As on December 31, 2016, Jubilant Life Sciences had a total of 73 ANDAs for Oral Solids filed in the US, of which 49 have been approved.
Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
